Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36982943)

  • 1. Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study.
    Titmuss E; Milne K; Jones MR; Ng T; Topham JT; Brown SD; Schaeffer DF; Kalloger S; Wilson D; Corbett RD; Williamson LM; Mungall K; Mungall AJ; Holt RA; Nelson BH; Jones SJM; Laskin J; Lim HJ; Marra MA
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.
    Jones MR; Schrader KA; Shen Y; Pleasance E; Ch'ng C; Dar N; Yip S; Renouf DJ; Schein JE; Mungall AJ; Zhao Y; Moore R; Ma Y; Sheffield BS; Ng T; Jones SJ; Marra MA; Laskin J; Lim HJ
    Ann Oncol; 2016 May; 27(5):801-6. PubMed ID: 27022066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.
    Ager EI; Wen SW; Chan J; Chong WW; Neo JH; Christophi C
    BMC Cancer; 2011 Jun; 11():274. PubMed ID: 21703011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-genome and transcriptome analysis enhances precision cancer treatment options.
    Pleasance E; Bohm A; Williamson LM; Nelson JMT; Shen Y; Bonakdar M; Titmuss E; Csizmok V; Wee K; Hosseinzadeh S; Grisdale CJ; Reisle C; Taylor GA; Lewis E; Jones MR; Bleile D; Sadeghi S; Zhang W; Davies A; Pellegrini B; Wong T; Bowlby R; Chan SK; Mungall KL; Chuah E; Mungall AJ; Moore RA; Zhao Y; Deol B; Fisic A; Fok A; Regier DA; Weymann D; Schaeffer DF; Young S; Yip S; Schrader K; Levasseur N; Taylor SK; Feng X; Tinker A; Savage KJ; Chia S; Gelmon K; Sun S; Lim H; Renouf DJ; Jones SJM; Marra MA; Laskin J
    Ann Oncol; 2022 Sep; 33(9):939-949. PubMed ID: 35691590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
    Pender A; Titmuss E; Pleasance ED; Fan KY; Pearson H; Brown SD; Grisdale CJ; Topham JT; Shen Y; Bonakdar M; Taylor GA; Williamson LM; Mungall KL; Chuah E; Mungall AJ; Moore RA; Lavoie JM; Yip S; Lim H; Renouf DJ; Sun S; Holt RA; Jones SJM; Marra MA; Laskin J
    Clin Cancer Res; 2021 Jan; 27(1):202-212. PubMed ID: 33020056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
    Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
    Front Immunol; 2022; 13():809971. PubMed ID: 35185898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibitory receptor CD94/NKG2A on CD8
    Eugène J; Jouand N; Ducoin K; Dansette D; Oger R; Deleine C; Leveque E; Meurette G; Podevin J; Matysiak T; Bennouna J; Bezieau S; Volteau C; Thomas WEA; Chetritt J; Kerdraon O; Fourquier P; Thibaudeau E; Dumont F; Mosnier JF; Toquet C; Jarry A; Gervois N; Bossard C
    Mod Pathol; 2020 Mar; 33(3):468-482. PubMed ID: 31409873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care.
    Weymann D; Laskin J; Jones SJM; Roscoe R; Lim HJ; Renouf DJ; Schrader KA; Sun S; Yip S; Marra MA; Regier DA
    J Community Genet; 2022 Oct; 13(5):523-538. PubMed ID: 34843087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer.
    Chen Y; Bai B; Ying K; Pan H; Xie B
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188775. PubMed ID: 35934154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The KARTAN study: a postmarketing assessment of Irbesartan in patients with hypertension.
    Morales-Olivas FJ; Arístegui I; Estañ L; Rodicio JL; Moreno A; Gil V; Ferrón G; Velasco O;
    Clin Ther; 2004 Feb; 26(2):232-44. PubMed ID: 15038946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy.
    Ghatalia P; Nagarathinam R; Cooper H; Geynisman DM; El-Deiry WS
    Cancer Biol Ther; 2017 Sep; 18(9):651-654. PubMed ID: 28726535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
    Schiffrin EL; Park JB; Pu Q
    J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.
    Maby P; Tougeron D; Hamieh M; Mlecnik B; Kora H; Bindea G; Angell HK; Fredriksen T; Elie N; Fauquembergue E; Drouet A; Leprince J; Benichou J; Mauillon J; Le Pessot F; Sesboüé R; Tuech JJ; Sabourin JC; Michel P; Frébourg T; Galon J; Latouche JB
    Cancer Res; 2015 Sep; 75(17):3446-55. PubMed ID: 26060019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
    J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety between two different irbesartan, generic vs branded, in the treatment of Korean patients with mild-to-moderate hypertension: an 8-week, multicenter, randomized, open-label, Phase IV clinical study.
    Han SH; Oh GC; Kwon HM; Park CG; Kim IJ; Hwang GS; Yoo BS; Park SH; Lee KJ; Kim HS
    Drug Des Devel Ther; 2018; 12():4217-4229. PubMed ID: 30587918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.
    Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J
    Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer.
    Guenter J; Abadi S; Lim H; Chia S; Woods R; Jones M; Rebic N; Renouf DJ; Laskin J; Marra M
    J Oncol Pharm Pract; 2021 Sep; 27(6):1371-1381. PubMed ID: 32847480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.